Kunming Longjin Pharmaceutical Yönetim

Yönetim kriter kontrolleri 1/4

We currently do not have sufficient information about the CEO.

Anahtar bilgiler

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	no data
CEO sahipliği	n/a
Yönetim ortalama görev süresi	Veri yok
Yönetim Kurulu ortalama görev süresi	3.9yrs

Son yönetim güncellemeleri

Recent updates

What Kunming Longjin Pharmaceutical Co., Ltd.'s (SZSE:002750) 38% Share Price Gain Is Not Telling You

Aug 14

Kunming Longjin Pharmaceutical Co., Ltd. (SZSE:002750) May Have Run Too Fast Too Soon With Recent 40% Price Plummet

Jun 30

Risks Still Elevated At These Prices As Kunming Longjin Pharmaceutical Co., Ltd. (SZSE:002750) Shares Dive 26%

Apr 26

We're Not Very Worried About Kunming Longjin Pharmaceutical's (SZSE:002750) Cash Burn Rate

Apr 17

Revenues Not Telling The Story For Kunming Longjin Pharmaceutical Co., Ltd. (SZSE:002750) After Shares Rise 29%

Mar 08

CEO

Kunming Longjin Pharmaceutical CEO'su yok ya da onlar hakkında elimizde veri yok.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Ya He Li	Deputy GM	16.8yrs	CN¥360.20k	Veri yok
Nan Wang	Independent Director	3.9yrs	CN¥56.30k	Veri yok
Xian'e Fan	Chairman of the Board	25.8yrs	CN¥884.90k	0.59% CN¥ 5.0m
Xiao Nan Zhou	Vice Chairman of the Board of Directors	no data	CN¥663.00k	Veri yok
Wen Guang Zi	Supervisor	no data	Veri yok	Veri yok
Chunyan Wen	Non-Independent Director	3.9yrs	CN¥73.00k	Veri yok
Lu Qiu	Non-Independent Director	3.9yrs	CN¥171.80k	Veri yok
Ping Liu	Chairman of the Supervisory Board	no data	Veri yok	Veri yok
Shuang Zhang	Independent Director	less than a year	CN¥16.00k	Veri yok
Hui Xu	Independent Director	less than a year	Veri yok	Veri yok
Lijuan Fan	Non-Independent Director	less than a year	CN¥360.50k	Veri yok
Lijun Wei	Independent Director	less than a year	Veri yok	Veri yok

3.9yrs

Ortalama Görev Süresi

48.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 002750's board of directors are considered experienced (3.9 years average tenure).

Kunming Longjin Pharmaceutical Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

Kunming Longjin Pharmaceutical Co., Ltd., Annual General Meeting, May 21, 2024

Kunming Longjin Pharmaceutical Co., Ltd. Approves Board Elections

Insufficient new directors

Kunming Longjin Pharmaceutical Co., Ltd., Annual General Meeting, May 25, 2022

Longjin Approves Election of Directors

Recent updates

Third quarter 2024 earnings released: CN¥0.013 loss per share (vs CN¥0.027 loss in 3Q 2023)

Kunming Longjin Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 26, 2024

Second quarter 2024 earnings released: EPS: CN¥0.001 (vs CN¥0.019 loss in 2Q 2023)

What Kunming Longjin Pharmaceutical Co., Ltd.'s (SZSE:002750) 38% Share Price Gain Is Not Telling You

Kunming Longjin Pharmaceutical Co., Ltd. (SZSE:002750) May Have Run Too Fast Too Soon With Recent 40% Price Plummet

Kunming Longjin Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 28, 2024

New minor risk - Market cap size

Kunming Longjin Pharmaceutical Co., Ltd., Annual General Meeting, May 21, 2024

Full year 2023 earnings released: CN¥0.18 loss per share (vs CN¥0.14 loss in FY 2022)

Risks Still Elevated At These Prices As Kunming Longjin Pharmaceutical Co., Ltd. (SZSE:002750) Shares Dive 26%

We're Not Very Worried About Kunming Longjin Pharmaceutical's (SZSE:002750) Cash Burn Rate

Kunming Longjin Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

Revenues Not Telling The Story For Kunming Longjin Pharmaceutical Co., Ltd. (SZSE:002750) After Shares Rise 29%

New major risk - Share price stability

Kunming Longjin Pharmaceutical Co., Ltd. Approves Board Elections

Insufficient new directors

Kunming Longjin Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Apr 30, 2024

Third quarter 2023 earnings released: CN¥0.027 loss per share (vs CN¥0.002 loss in 3Q 2022)

Kunming Longjin Pharmaceutical Co., Ltd. to Report Q3, 2023 Results on Oct 31, 2023

Second quarter 2023 earnings released: CN¥0.019 loss per share (vs CN¥0.008 loss in 2Q 2022)

Full year 2022 earnings released: CN¥0.14 loss per share (vs CN¥0.008 profit in FY 2021)

Third quarter 2022 earnings released: CN¥0.002 loss per share (vs CN¥0.004 profit in 3Q 2021)

Second quarter 2022 earnings released: CN¥0.008 loss per share (vs CN¥0.006 profit in 2Q 2021)

Kunming Longjin Pharmaceutical Co., Ltd., Annual General Meeting, May 25, 2022

Full year 2021 earnings: EPS exceeds analyst expectations

Third quarter 2021 earnings released: EPS CN¥0.004 (vs CN¥0.01 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.006 (vs CN¥0.006 in 2Q 2020)

Full year 2020 earnings released: EPS CN¥0.03 (vs CN¥0.058 loss in FY 2019)

Kunming Longjin Pharmaceutical Co., Ltd. to Report Fiscal Year 2020 Results on Apr 15, 2021

New 90-day low: CN¥7.85

Longjin Approves Election of Directors

New 90-day high: CN¥11.42

New 90-day low: CN¥7.27

Third quarter earnings released

New 90-day low: CN¥8.12

New 90-day low - CN¥8.88

Earnings released

Kunming Longjin Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 25, 2020

Kunming Longjin Pharmaceutical Co., Ltd. (SZSE:002750) completed the acquisition of Yunnan 37 Technology Dengzhanhua Pharmaceutical Co., Ltd. and Yunnan 37 Technology Dengzhanhua Planting from Yunnan 37 Technology Co., Ltd.

CEO

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş